- Iraq: 60 dead in attack on prisoner convoy
- Marco Rubio: U.S. at social, moral crossroads
- ‘We’re coming for you, Barack Obama’: Top U.S. official discloses threat from ISIL
- White flags baffle NYPD: ‘We’re lucky it wasn’t a bomb’
- N.Y. Gov. Cuomo’s office interfered with, pressured corruption commission: report
- Brit lawmaker: I would fire on Israel if I lived in Gaza
- VA apologizes to forgotten Marine veteran locked in Fla. clinic, forced to call 911
- U.S. social and economic trends on worrisome track, survey finds
- McDonald nomination unanimously referred to full Senate
- Chuck Norris honorary chairman of NRA voter registration campaign
Bayer clotting drug meets late-stage study’s goal
Question of the Day
TRENTON, N.J. (AP) - Bayer HealthCare Pharmaceuticals said Tuesday that its experimental, genetically engineered treatment for the most common type of bleeding disorder hemophilia met its main goal of reducing treatment frequency in a late-stage patient study.
The medicine, called BAY 94-9027, helped prevent damaging internal bleeding in patients when given less frequently than standard treatments, which many patients need every other day. Bayer’s treatment helps prevent bleeding episodes when infused - or given through a slow intravenous drip through a tube - as a preventive treatment twice per week, every five days and even every seven days. The medicine also stopped bleeding when it did occur.
The 134 patients in the study all have hemophilia A, the most common type. It affects about one in 5,000 newborn boys, for a total of about 20,000 American males.
The generally inherited disorder occurs when a type of protein needed to cause clotting, called Factor VIII, is missing or at inadequate levels. There is no cure, and without preventive treatment with clotting medicines, repeated episodes of uncontrolled bleeding in the joints and eyes cause pain, increasing disability and a shortened lifespan.
Bayer’s drug is a genetically engineered version of the Factor VIII clotting protein, with an attachment site added, to which a protective molecule binds. This keeps the clotting protein active much longer as it circulates through the bloodstream, enabling patients to go longer between their pricey infusions.
Bayer is doing further studies on the medicine, including testing its safety in children and during major surgery, and the company plans a new study in patients not previously treated with similar anticlotting medicines.
Bayer HealthCare, based in Whippany, N.J., makes prescription drugs, veterinary medicines and consumer health products. It’s part of part of German conglomerate Bayer AG, which also makes chemicals for farming and high-tech materials.
TWT Video Picks
The subsidies are a hit with patients who don't exist
- Obama orders Pentagon advisers to Ukraine
- 'We're coming for you, Barack Obama': Top U.S. official discloses threat from ISIL terrorists
- Hezbollah warring in Syria could join fight against Israel
- Hamas orders civilians to die in Israeli airstrikes
- Obama pressed on Sudanese mother's case, facing death sentence over Christian faith
- Netanyahu's Wikipedia page replaced with giant Palestinian flag
- House task force to recommend National Guard on border, faster deportations
- Democratic Sen. John Walsh plagiarized War College master's thesis: report
- EDITORIAL: Poor Hillary, rock-star wannabe
- Family removed from Southwest flight over tweet about rude agent, dad says
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world
Fighting in Iraq